NOVN - Novan, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
2.4200
-0.0400 (-1.63%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close2.4600
Open2.4220
Bid2.3900 x 1400
Ask4.0000 x 800
Day's Range2.3700 - 2.4700
52 Week Range0.6500 - 3.2400
Volume9,181
Avg. Volume84,495
Market Cap63.089M
Beta (3Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-0.9590
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Lean-running Triangle drugmaker to drastically shrink its office space
    American City Business Journals

    Lean-running Triangle drugmaker to drastically shrink its office space

    After scraping by in a battle against running out of funds, a Triangle drugmaker continues to cut weight with plans to reduce its headquarters by 70 percent

  • GlobeNewswire

    Novan Advances Women’s Health Business Unit with Non-Dilutive Funding

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has received a federal grant from the National Institutes of Health (NIH). In addition, the Company anticipates receiving an additional federal grant in the very near term.

  • GlobeNewswire

    Novan Takes Steps to Reduce Real Estate Footprint

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has executed a non-binding letter of intent (LOI) with a third party on its facility at 4105 Hopson Road in Morrisville, NC. The primary goal of the LOI is to negotiate an agreement that obtains the release of Novan from its current multi-year obligation. The Company’s objective is to reach a binding agreement no later than the end of the third quarter of 2019.

  • GlobeNewswire

    Novan’s Phase 3 Molluscum Pivotal Program Completes Enrollment

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has recently completed patient recruitment in the Company’s ongoing “B-SIMPLE” (Berdazimer Sodium In Molluscum Patients with Lesions) Phase 3 pivotal trials with SB206 for the treatment of molluscum contagiosum. The trials enrolled approximately 680 patients with 3 to 70 molluscum lesions at Baseline.

  • Analysts Estimate Novan (NOVN) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Novan (NOVN) to Report a Decline in Earnings: What to Look Out for

    Novan (NOVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Novan’s Drug Substance Demonstrates Inhibition of HPV-18 Virus Production

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that independently generated preclinical data which demonstrated the antiviral effects of the Company’s nitric oxide-releasing macromolecule, NVN1000, on human papillomavirus (HPV) infections has been published in Antiviral Research. The study was conducted by a research team from the Department of Biochemistry and Molecular Genetics at the University of Alabama at Birmingham led by N. Sanjib Banerjee, Ph.D., Thomas R. Broker, Ph.D., Founding President of the International Papillomavirus Society, and Louise T. Chow, PhD, Member of the U.S. National Academy of Sciences and of Academia Sinica (Taiwan).

  • GlobeNewswire

    Novan SB206 Phase 3 Molluscum Pivotal Program Update

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has exceeded 50 percent of expected patient enrollment in the Company’s ongoing “B-SIMPLE” (Berdazimer Sodium In Molluscum Patients with Lesions) Phase 3 pivotal trials. The studies are designed to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum.

  • Does Market Volatility Impact Novan, Inc.'s (NASDAQ:NOVN) Share Price?
    Simply Wall St.

    Does Market Volatility Impact Novan, Inc.'s (NASDAQ:NOVN) Share Price?

    If you're interested in Novan, Inc. (NASDAQ:NOVN), then you might want to consider its beta (a measure of share price...

  • Is Novan, Inc. (NASDAQ:NOVN) A Volatile Stock?
    Simply Wall St.

    Is Novan, Inc. (NASDAQ:NOVN) A Volatile Stock?

    Anyone researching Novan, Inc. (NASDAQ:NOVN) might want to consider the historical volatility of the share price...

  • GlobeNewswire

    Novan Expands External Business Partner Network

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced continued business advancements in both formulation science and manufacturing. Novan has expanded its relationship with MedPharm Ltd (“MedPharm”).

  • GlobeNewswire

    Novan to Participate in JMP Securities Life Sciences Conference

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that it will participate in the 2019 JMP Securities Life Sciences Conference in New York on Thursday, June 20, 2019. Participation will include a fireside chat as well as a Q&A session. The fireside chat will occur on June 20, 2019 at 9:30 a.m. Eastern.

  • GlobeNewswire

    Novan Achieves Compliance with Nasdaq Listing Rule 5450(b)(2)(A)

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5450(b)(2)(A). This rule requires a minimum $50 million market value of listed securities in order to maintain a listing on The Nasdaq Global Market. The Company previously received a non-compliance notification from Nasdaq on January 14, 2019.

  • GlobeNewswire

    First Patient Enrolled and Dosed in Novan’s SB206 Phase 3 Molluscum Program

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the first patient has been dosed in the Company’s “B-SIMPLE” (Berdazimer Sodium In Molluscum Patients with Lesions) Phase 3 program. The study is designed to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum. The B-SIMPLE Phase 3 program consists of two multi-center, randomized, double-blind, vehicle-controlled studies, B-SIMPLE1 and B-SIMPLE2.

  • GlobeNewswire

    Novan Announces 2019 Annual Meeting of Stockholders for July 31, 2019

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that it will hold its 2019 Annual Meeting of Stockholders on Wednesday, July 31, at 9:30 am Eastern Time, at the Company’s corporate headquarters located at 4105 Hopson Road, Morrisville, NC 27560. Stockholders of record as of the close of business on June 7, 2019 are entitled to notice of and to vote at the 2019 Annual Meeting. The date of the 2019 Annual Meeting represents a change of more than 30 days from the anniversary of the Company’s 2018 Annual Meeting.

  • Executive Voice: She raises cash, and hope, for struggling Novan
    American City Business Journals

    Executive Voice: She raises cash, and hope, for struggling Novan

    When Paula Brown Stafford – an accomplished life sciences executive who spent the better part of three decades at Quintiles – took over as president and chief operating officer of Novan (Nasdaq: NOVN), the situation at the company was far from ideal.  The Morrisville drug company has been battling to advance its pipeline of drugs treating skin disorders without the use of antibiotics, but its runway was getting short. Just weeks afterward, Nasdaq sent the company a letter informing it that Novan’s value had dropped so low it would be delisted in July – unless it could raise the stock’s value to higher than $1.92 per share.

  • With a fresh $30 million, Durham pharma set to expand drug pipeline
    American City Business Journals

    With a fresh $30 million, Durham pharma set to expand drug pipeline

    With a $30 million investment from a single Cary-based firm, one Durham pharmaceutical company is "set loose" to run multiple trials.

  • GlobeNewswire

    Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the treatment of atopic dermatitis and Phase 2 trial with SB206 gel for the treatment of molluscum contagiosum will be presented at the 77th Annual Meeting of the Annual Meeting of the Society for Investigative Dermatology. Clinical and biomarker results from the Company’s Phase 1b atopic dermatitis trial will be presented during an oral presentation on May 9, 2019 and during a poster session on May 11, 2019.

  • Novan adds more cash, now confident it can execute
    American City Business Journals

    Novan adds more cash, now confident it can execute

    In an continued effort to fund the company without hurting its already-down stock value, Novan has announced another $12 million deal to forward its lead drug trials.

  • GlobeNewswire

    Novan Completes Funding Transaction with Ligand Pharmaceuticals

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has secured $12 million in non-dilutive capital from Ligand Pharmaceuticals Incorporated (“Ligand”) (LGND). This transaction further enables the accelerated advancement of the molluscum Phase 3 program within the overall Novan mid-to-late stage clinical development portfolio. Under the terms of this development funding and royalty agreement, Ligand will provide funding of $12 million in exchange for a tiered royalty of 7 to 10% which will be based on future North American sales of SB206 for the molluscum indication.

  • GlobeNewswire

    Novan Confirms Corporate Update Conference Call and Webcast

    Novan, Inc. ("the Company" or "Novan") (NOVN) today confirmed that the Company will host a conference call tomorrow, Thursday, May 2, 2019 at 8:15 am Eastern Time to provide an update on the Company’s recent financing, clinical development plan and business model.

  • Cash-starved Novan adds capital, but at a price
    American City Business Journals

    Cash-starved Novan adds capital, but at a price

    With just a over a month of its cash runway left, Novan has come up big with $35 million – but that capital comes with strings attached.

  • GlobeNewswire

    Novan Secures Up to $35 Million in Non-Dilutive Funding

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has secured up to $35 million in non-dilutive capital to advance Novan’s late-stage dermatology assets. Of this, $25 million is available immediately and $10 million is contingent upon achieving positive Phase 3 clinical trial results for molluscum contagiosum. This funding will allow Novan to immediately initiate the pivotal Phase 3 molluscum program.

  • Novan stock plummets as Durham company searches for additional financing
    American City Business Journals

    Novan stock plummets as Durham company searches for additional financing

    One of the Triangle’s public companies continues to face hardships, as Novan’s stock dives away from the value it needs to stay on the stock exchange.